<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096625</url>
  </required_header>
  <id_info>
    <org_study_id>tDCS ATP</org_study_id>
    <nct_id>NCT04096625</nct_id>
  </id_info>
  <brief_title>Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS)</brief_title>
  <official_title>Enhancement of a Psychotherapeutic Intervention Through Transcranial Direct Current Stimulation (tDCS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric University Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric University Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial Direct Current Stimulation (tDCS), is a neuromodulatory technique, that is safe,&#xD;
      well-tolerated, easy to administer and fairly inexpensive. Results from tDCS trials involving&#xD;
      participants with several neuropsychiatric disorders, including major depression, bipolar&#xD;
      disorder, schizophrenia and substance use disorder are encouraging. The clinical effects of&#xD;
      tDCS are broad; the underlying condition, the areas stimulated together with the type and&#xD;
      duration of stimulation are important factors. In patients with neuropsychiatric conditions,&#xD;
      a reduction of symptoms, an enhancement of neurocognitive functions together with an overall&#xD;
      improvement in functionality and wellbeing have been consistently reported. These effects&#xD;
      emerge during the stimulation period, in the weeks after stimulation, the effects seem to&#xD;
      peak and consolidate further. tDCS appears to enhance the effects of other interventions as&#xD;
      well; however, to date, there have been no studies into the effects of using tDCS as an&#xD;
      add-on intervention to psychotherapy on symptoms and wellbeing&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The investigators plan a double-blind, randomised, sham-controlled trial in a cross-over design to assess the efficacy and safety of tDCS as an add-on intervention to a psychotherapeutic treatment for patients with a severe psychiatric condition requiring hospitalization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychopathological Assessment</measure>
    <time_frame>Change: Baseline, 3, 6 weeks, 6 and 12 months</time_frame>
    <description>Symptom Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insecurity- Self-confidence</measure>
    <time_frame>Change: Baseline, 3, 6 weeks, 6 and 12 months</time_frame>
    <description>Symptom Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Psychiatric Disorder</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active tDCS will be delivered at 2mA for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS: after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>Active tDCS will be delivered at 2mA for 20 minutes.</description>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assertiveness Training Program (ATP)</intervention_name>
    <description>The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.</description>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).</description>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are competent to give informed consent, as determined by the referring&#xD;
             physician or psychiatrist.&#xD;
&#xD;
          -  German language proficiency as a native speaker or level B1&#xD;
&#xD;
          -  A psychiatric diagnosis according to ICD-10;&#xD;
&#xD;
          -  Three or more psychiatric hospitalizations in the past 12 months; or&#xD;
&#xD;
          -  A cumulative length of stay over 40 days; or&#xD;
&#xD;
          -  Referral for further treatment to our treatment unit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant group psychotherapeutic intervention.&#xD;
&#xD;
          -  Current neurological disorder.&#xD;
&#xD;
          -  Current cardiovascular disorder.&#xD;
&#xD;
          -  Current respiratory disorder.&#xD;
&#xD;
          -  Current substance use or withdrawal.&#xD;
&#xD;
          -  Epilepsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan T. Egger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric University Hospital of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan T. Egger, MD</last_name>
    <phone>+41523049340</phone>
    <email>stephan.egger@puk.zh.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Psychiatrische Universitätsklinik Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan T Egger, MD</last_name>
      <phone>+4152304940</phone>
      <email>stephan.egger@puk.zh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Godehard Weniger, MD</last_name>
      <phone>+41523049341</phone>
      <email>godehard.weniger@puk.zh.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric University Hospital, Zurich</investigator_affiliation>
    <investigator_full_name>Stephan T. Egger</investigator_full_name>
    <investigator_title>Senior Psychiatrists</investigator_title>
  </responsible_party>
  <keyword>Brain Stimulation, tDCS, Psychotherapy, Psychiatric Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

